SE9600233L - Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori - Google Patents

Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori

Info

Publication number
SE9600233L
SE9600233L SE9600233A SE9600233A SE9600233L SE 9600233 L SE9600233 L SE 9600233L SE 9600233 A SE9600233 A SE 9600233A SE 9600233 A SE9600233 A SE 9600233A SE 9600233 L SE9600233 L SE 9600233L
Authority
SE
Sweden
Prior art keywords
preparation
pct
helicobacter pylori
date jul
drug against
Prior art date
Application number
SE9600233A
Other languages
English (en)
Other versions
SE9600233D0 (sv
SE506529C2 (sv
Inventor
Carl Olof Claesson
Gustaf Lindewald
Original Assignee
Semper Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Semper Ab filed Critical Semper Ab
Priority to SE9600233A priority Critical patent/SE506529C2/sv
Publication of SE9600233D0 publication Critical patent/SE9600233D0/sv
Priority to JP9526782A priority patent/JP2000509367A/ja
Priority to AU15627/97A priority patent/AU731221B2/en
Priority to DE69714083T priority patent/DE69714083T2/de
Priority to US09/117,029 priority patent/US6149908A/en
Priority to EP97901880A priority patent/EP1007086B1/en
Priority to AT97901880T priority patent/ATE220556T1/de
Priority to CA002243708A priority patent/CA2243708C/en
Priority to PCT/SE1997/000098 priority patent/WO1997026908A1/sv
Publication of SE9600233L publication Critical patent/SE9600233L/sv
Publication of SE506529C2 publication Critical patent/SE506529C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
    • C12Y101/03004—Glucose oxidase (1.1.3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SE9600233A 1996-01-23 1996-01-23 Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori SE506529C2 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE9600233A SE506529C2 (sv) 1996-01-23 1996-01-23 Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori
PCT/SE1997/000098 WO1997026908A1 (sv) 1996-01-23 1997-01-22 Antibakteriell komposition mot helicobacter
US09/117,029 US6149908A (en) 1996-01-23 1997-01-22 Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating Helicobacter pylori infection
AU15627/97A AU731221B2 (en) 1996-01-23 1997-01-22 Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating helicobacter pylori infection
DE69714083T DE69714083T2 (de) 1996-01-23 1997-01-22 Die verwendung von lactoperoxidase, einem peroxiddonor und thiocyanat zur herstellung eines medikaments zur behandlung einer infektion mit helicobacter pylori
JP9526782A JP2000509367A (ja) 1996-01-23 1997-01-22 ヘリコバクタピロリ感染の治療用医薬を製造するためのラクトペルオキシダーゼ、ペルオキシドドナーおよびチオシアネートの使用
EP97901880A EP1007086B1 (en) 1996-01-23 1997-01-22 Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating helicobacter pylori infection
AT97901880T ATE220556T1 (de) 1996-01-23 1997-01-22 Die verwendung von lactoperoxidase, einem peroxiddonor und thiocyanat zur herstellung eines medikaments zur behandlung einer infektion mit helicobacter pylori
CA002243708A CA2243708C (en) 1996-01-23 1997-01-22 Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating helicobacter pylori infection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9600233A SE506529C2 (sv) 1996-01-23 1996-01-23 Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori

Publications (3)

Publication Number Publication Date
SE9600233D0 SE9600233D0 (sv) 1996-01-23
SE9600233L true SE9600233L (sv) 1997-07-24
SE506529C2 SE506529C2 (sv) 1997-12-22

Family

ID=20401114

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9600233A SE506529C2 (sv) 1996-01-23 1996-01-23 Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori

Country Status (9)

Country Link
US (1) US6149908A (sv)
EP (1) EP1007086B1 (sv)
JP (1) JP2000509367A (sv)
AT (1) ATE220556T1 (sv)
AU (1) AU731221B2 (sv)
CA (1) CA2243708C (sv)
DE (1) DE69714083T2 (sv)
SE (1) SE506529C2 (sv)
WO (1) WO1997026908A1 (sv)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19710068A1 (de) * 1997-03-12 1998-09-17 Kramer Axel Mittel zur Förderung der Mundhygiene und der Mundgesundheit
US5972355A (en) * 1997-09-30 1999-10-26 E-L Management Corp. Stable compositions containing biologically active components
DK1028628T3 (da) 1997-11-05 2003-06-16 Koppert Bv Pesticid mod plantepatogene mikroorganismer
US6190667B1 (en) * 1998-06-30 2001-02-20 Institut Pasteur Methods of inhibiting Helicobacter pylori
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
DE60033019D1 (de) * 1999-03-17 2007-03-08 Morinaga & Co Arzneimittel, nahrungsmittel, getränke und futter enthaltend eine kakao-komponente
US6342528B1 (en) * 2000-01-18 2002-01-29 Lynntech, Inc. Control of microbial populations in the gastrointestinal tract of animals
AU2001283462A1 (en) * 2000-08-21 2002-03-04 Jed W. Fahey Treatment of helicobacter with isothiocyanates
WO2002069958A1 (de) * 2001-03-01 2002-09-12 Wolfgang Weuffen Thiocyanationen zur vorbeugung und therapie von bse und ähnlichen erkrankungen beim tier und menschen
US6702998B2 (en) * 2001-05-15 2004-03-09 Gregory E. Conner Methods and devices for treating lung dysfunction
US7770577B2 (en) 2001-05-15 2010-08-10 Gregory E Conner Methods and devices for treating lung dysfunction
SE0200876L (sv) * 2002-03-22 2003-09-23 Krister Tano Nässpray mot öroninflammationer
NZ537089A (en) 2003-02-24 2007-07-27 Morinaga Milk Industry Co Ltd Interleukin 6 production inhibitor
WO2005018701A1 (en) * 2003-08-25 2005-03-03 Kane Biotech Inc. Synergistic antimicrobial compositions and methods of inhibiting biofilm formation
ES2395937T3 (es) 2004-02-17 2013-02-18 Morinaga Milk Industry Co., Ltd. Proceso para producir lactoperoxidasa
US20060289354A1 (en) * 2005-06-15 2006-12-28 Buckman Laboratories International, Inc. Method and composition to control the growth of microorganisms in aqueous systems and on substrates
US20070092502A1 (en) * 2005-09-01 2007-04-26 Allergan, Inc. Method of Treating Glaucoma
JP4979596B2 (ja) * 2006-01-20 2012-07-18 森永乳業株式会社 腸疾患のための医薬組成物、飲食品、又は飼料
US20070197388A1 (en) * 2006-02-22 2007-08-23 Buckman Laboratories International, Inc. Haloperoxidase treatment to control algae
DK2392343T3 (en) * 2006-07-03 2019-01-28 Perraudin Jean Paul Antimicrobial compositions comprising hypohalite and / or hypothiocyanite and applications thereof
GB0705557D0 (en) * 2007-03-23 2007-05-02 Stead Richard G A treatment
EP2276505B1 (en) * 2008-03-20 2013-09-18 TANO, Krister Nasal spray or nasal drops for treatment of common cold
TWI480272B (zh) 2008-10-09 2015-04-11 Anadys Pharmaceuticals Inc 藉由５，６－二氫－１ｈ－吡啶－２－酮與一或多種其他抗病毒化合物的組合物抑制ｃ型肝炎病毒的方法
JP2009215301A (ja) * 2009-04-27 2009-09-24 Morinaga Milk Ind Co Ltd プロテアーゼ阻害剤
NZ600269A (en) * 2009-05-20 2014-02-28 Dec Int Nz Ltd Delivery device for treatment of mastitis
CN102858356A (zh) * 2010-02-24 2013-01-02 森永乳业株式会社 以海带提取物为有效成分的抗菌辅助剂、抗菌组合物、以及饮食品
US10273205B2 (en) 2011-01-03 2019-04-30 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms
US10647668B2 (en) 2011-01-03 2020-05-12 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US10308599B2 (en) 2011-01-03 2019-06-04 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US9962361B2 (en) 2011-01-03 2018-05-08 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US11407713B2 (en) 2011-01-03 2022-08-09 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US11279674B2 (en) 2011-01-03 2022-03-22 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
US8933119B2 (en) 2011-01-03 2015-01-13 The William M. Yarbrough Foundation Method for treating phytophotodermatitis
US8865765B2 (en) 2011-01-12 2014-10-21 The William M. Yarbrough Foundation Method for treating eczema
US9532969B2 (en) 2011-02-08 2017-01-03 The William M. Yarbrough Foundation Method for treating psoriasis
US8865772B2 (en) 2012-07-26 2014-10-21 The William M. Yarbrough Foundation Method for treating skin cancer
US10434082B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
US9949943B2 (en) 2012-07-26 2018-04-24 The William M. Yarbrough Foundation Method for treating neurodegenerative diseases
US10335387B2 (en) 2012-07-26 2019-07-02 The William M. Yarbrough Foundation Method for treating infectious diseases with isothiocyanate functional compounds
US10080734B2 (en) 2012-07-26 2018-09-25 The William M. Yarbrough Foundation Method for treating autism and other neurodevelopmental disorders
US9839621B2 (en) 2012-07-26 2017-12-12 The William M. Yarbrough Foundation Method for treating bladder cancer
US10434081B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Inhibitors of macrophage migration inhibitory factor
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
EP2925167A1 (en) 2012-11-30 2015-10-07 DSM IP Assets B.V. Synergistic fungicidal compositions containing lactoperoxidase system
EP3245871A1 (en) 2014-04-30 2017-11-22 Matoke Holdings Limited Antimicrobial compositions
WO2016059654A1 (en) * 2014-10-16 2016-04-21 Giuseppe Baricco Use of glucose oxidase for the control, the prevention and the cure of intestinal disorders
GB2540130B (en) * 2015-06-29 2021-04-14 Institute Of Tech Sligo A composition and a method for controlling bacterial infection
GB201716986D0 (en) 2017-10-16 2017-11-29 Matoke Holdings Ltd Antimicrobial compositions
WO2024017883A1 (en) 2022-07-18 2024-01-25 Acies Bio D.O.O. Peroxidase based biocontrol agents
EP4309500A1 (en) 2022-07-18 2024-01-24 Acies Bio d.o.o. Peroxidase based biocontrol agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE420793B (sv) * 1976-03-08 1981-11-02 Astra Ewos Ab Fodermedel innehallande ett antibakteriellt system
US4578265A (en) * 1981-08-13 1986-03-25 Laclede Professional Products, Inc. Di-enzymatic dentifrice
US4564519A (en) * 1983-06-06 1986-01-14 Laclede Professional Products, Inc. Di-enzymatic chewable dentifrice
DK501686A (da) * 1986-10-20 1988-04-21 Otto Melchior Poulsen Enzymholdigt, baktericidt middel samt tandplejemidler og saarbehandlingsmidler, som indeholder det
SE469004B (sv) * 1989-03-07 1993-04-26 Nobeltech Electronics Ab Nattkikare
FR2646777B1 (fr) * 1989-05-12 1993-09-03 Bio Serae Lab Procede de preparation d'un produit particulaire antimicrobien, produit antimicrobien obtenu et applications
GB9002422D0 (en) * 1990-02-03 1990-04-04 Boots Co Plc Anti-microbial compositions
US5453284A (en) * 1993-01-29 1995-09-26 Pellico; Michael A. Stabilized enzymatic dentifrice
US5336494A (en) * 1993-01-29 1994-08-09 Pellico Michael A Pet chewable products with enzymatic coating

Also Published As

Publication number Publication date
DE69714083D1 (de) 2002-08-22
CA2243708C (en) 2007-04-24
CA2243708A1 (en) 1997-07-31
SE9600233D0 (sv) 1996-01-23
JP2000509367A (ja) 2000-07-25
SE506529C2 (sv) 1997-12-22
DE69714083T2 (de) 2003-03-27
AU1562797A (en) 1997-08-20
AU731221B2 (en) 2001-03-29
US6149908A (en) 2000-11-21
WO1997026908A1 (sv) 1997-07-31
EP1007086A1 (en) 2000-06-14
EP1007086B1 (en) 2002-07-17
ATE220556T1 (de) 2002-08-15

Similar Documents

Publication Publication Date Title
SE9600233L (sv) Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori
Sherman et al. Maggot therapy: a review of the therapeutic applications of fly larvae in human medicine, especially for treating osteomyelitis
ATE237285T1 (de) Medizinisches implantat
AUPN531195A0 (en) Lipid extract having anti-inflamatory activity
SE8800266L (sv) Kopplingsanordning i hudgenomgaang
MD970199A (en) Induction of a cytotoxic T-lymphocytic answer The invention relates to the medicine, particularly to the immunology and can be used for treatment of bacterial and parasitic infections, tumors and other diseases. The summary of the invention consists in the induction of a cytotoxic T-lymphocytic answer to human and animals by means of a composition consisting of an antigene and an antigenic formulati
ES2128041T3 (es) Vendaje de aplicacion medica.
NZ266475A (en) Use of recombinant adenovirus of animal origin in making pharmaceutical composition
FR2721198B1 (fr) Prothèse implantable souple, utilisée en chirurgie pour l'augmentation de volume ou la reconstruction des tissus mous, notamment prothèse mammaire.
MY124714A (en) Enzyme treatment
GR3029496T3 (en) Implantable moulded body for administering active substances to plants
NZ510153A (en) Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals
LTIP1534A (en) Medicinal preparations for prophylaxis and treating metabolic disturbance of lipoids and cholesterin
ATA113492A (de) Mehrfachbeutelsystem zur sterilen behandlung von menschlichen blutkonserven
AU5643299A (en) Humic acid and its use in the treatment of various conditions
IL134762A (en) 8a-AZALIDES FOR TREATMENT OF BACTERIAL RESPIRATORY OR ENTERIC INFECTION IN A LIVESTOCK ANIMAL
RU2072692C1 (ru) Штамм бактерий lactobacillus helveticus, обладающий способностью снижать уровень холестерина в крови и используемый для получения препаратов и продуктов питания для профилактики и лечения гиперхолестеринемий
ATE71299T1 (de) Pharmazeutische zubereitung zur behandlung bakterieller infektionen.
Krizek Wound and reconstructive problems in advanced disease
Gray et al. Chronic swine instrumentation techniques utilizing the GOR-REX peritoneal catheter
ZA983211B (en) Use of mizolastine for preparing medication for the treatment of inflammation
RU94033173A (ru) Способ повышения репродуктивной функции мужчин
KR19990070169A (ko) 악창(암)치료
NZ329311A (en) use of beta-casein to inhibit infection in mammalian cells by respiratory syncytial virus
UA31364A (uk) Спосіб лікування дисбактеріозу кишечнику у хворих на гострий пієлонефрит

Legal Events

Date Code Title Description
NUG Patent has lapsed